Introduction: Breast cancer is the most common cancer among women in India and globally and the leading cause of cancer mortality among females. Early stage breast cancer (>60%) is common in the western population with 72.7% Luminal A sub type, 12.2% TNBC , 15-25% HER2 positive and 12% unknown status. In India, the locally advanced breast cancer (LABC) constitutes 50 to 60% of the patients presenting for treatment and 6–25% have metastases with 51.2% Luminal A and Luminal B subtype, 16.7% HER2neu positive and 29.8% triple negative. The 5 year disease free survival (DFS) rate of 70% and overall survival rate of 78% for early breast cancer.
Materials and methods: All cases of breast cancer who were treated in the Department of Medical Oncology, Madurai from January 2017 to December 2020 were included in the study. Out of 400 patients 323 breast cancer patients were analysed for Immuno Histo Chemistry.
Results: Among 323 patients, 54.79% has hormonal receptor positivity, 19.50% triple negative, 25.69% HER2 enriched.
Discussion: Prevalence of TNBC in India is considerably higher compared with Western populations as suggested by various meta-analysis studies with Indian trial having 51.2% HR positive tumours, HER2 positive tumours in 16.7% and TNBC in 29.8%. In our study, 54.79% has hormonal receptor positivity, 19.50% triple negative, 25.69% HER2 enriched.
Conclusion: The breast cancer is the most common cancer and the leading cause of cancer mortality among females. In our study we found that higher percentage of TNBC compared to western countries.
Impact Factor
2022: 6.012
This work is licensed under a